WuXi Biologics Cayman. has filed a patent for anti-CD39 antibodies that target human CD39, inhibiting its enzymatic activity. The claim outlines specific amino acid sequences for the heavy and light chain variable regions of the antibodies. GlobalData’s report on WuXi Biologics Cayman gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on WuXi Biologics Cayman, Personalized cancer vaccines was a key innovation area identified from patents. WuXi Biologics Cayman's grant share as of January 2024 was 18%. Grant share is based on the ratio of number of grants to total number of patents.
Anti-cd39 antibody for inhibiting human cd39 enzymatic activity
A patent application (Publication Number: US20240034803A1) has been filed for an anti-CD39 antibody that specifically binds to human CD39. The antibody comprises a heavy chain variable region and a light chain variable region with specific amino acid sequences. The patent claims cover various configurations of the antibody, including different complementarity determining regions and sequence identities. Additionally, the patent includes claims related to the antibody being a monoclonal antibody or an antigen-binding fragment, as well as variants of the heavy chain constant region.
Furthermore, the patent application includes claims for methods of inhibiting CD39 enzymatic activity, increasing extracellular ATP, activating the immune system, and treating or prophylaxis of cancer using the anti-CD39 antibody. The patent also covers combinations with additional therapeutic agents, pharmaceutical compositions, isolated polynucleotides encoding the antibody, host cells containing the polynucleotide, methods of expressing the antibody, and kits containing the antibody. The patent application provides a comprehensive overview of the anti-CD39 antibody and its potential applications in various therapeutic contexts.
To know more about GlobalData’s detailed insights on WuXi Biologics Cayman, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
